MedTrace Logo

Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

NCT06484985 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-01-28

No results posted yet for this study

Summary

This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.

Conditions

Interventions

DRUG

AXT-1003

AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.

Sponsors & Collaborators

  • Axter Therapeutics (Beijing) Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Qian Gao · Axter Therapeutics (Beijing) Co., Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-04
Primary Completion
2027-03-31
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06484985 on ClinicalTrials.gov